The Pharmaletter

One To Watch

Verastem Oncology

A late-stage biopharma company developing new medicines for patients with RAS/MAPK pathway-driven cancers.

The company's pipeline is focused on RAS/MAPK-driven cancers, specifically novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition and KRAS G12D inhibition.

Want to Update your Company's Profile?


More Verastem Oncology news >